이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

급성 골수성 백혈병 환자 치료에서 기증자 이식 및 시클로포스파미드 전 골수 및 림프계 총 방사선 조사

2026년 9월 30일 업데이트: City of Hope Medical Center

동종이계 조혈모세포이식(HCT) 전 총 골수/림프양 방사선 조사(TMLI) 조건화에 대한 예비 연구, 완전 관해 상태의 급성 골수성 백혈병에 대한 이식 후 시클로포스파미드 기반 이식 대 숙주 질환 예방

This pilot phase I trial studies the side effects of total bone marrow and lymphoid irradiation and how well it works with cyclophosphamide in treating patients with acute myeloid leukemia. Total marrow and lymphoid irradiation targets cancer in bone marrow and blood, instead of applying radiation to the whole body. Giving total bone marrow and lymphoid irradiation before a donor transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving total bone marrow and lymphoid irradiation before donor transplant and cyclophosphamide after transplant may work better at treating acute myeloid leukemia.

연구 개요

상세 설명

PRIMARY OBJECTIVE:

I. To evaluate the safety/feasibility of combining a total marrow and lymphoid irradiation (TMLI) transplant conditioning regimen with a post-transplant high dose cyclophosphamide (PTCy)-based graft versus host disease (GvHD) prophylaxis strategy, through the assessment of: adverse events: type, frequency, severity, attribution, time course, duration and complications: including acute GvHD, infection and delayed neutrophil/platelet engraftment.

SECONDARY OBJECTIVES:

I. To estimate the cumulative incidence (CI) of acute GvHD at 100 days post allogeneic hematopoietic cell transplantation (alloHCT).

II. To estimate the CI of chronic GvHD at 6 months, 1- and 2-years post alloHCT.

III. To estimate GVHD-free relapse-free survival (GRFS) at 1- and 2-years post alloHCT.

IV. To describe the kinetics of immune reconstitution and T cell repertoire in the first year post alloHCT.

V. To estimate overall survival (OS), relapse-free survival (RFS) and CI of relapse, and non-relapse mortality (NRM) at 100 days, 1- and 2-years post alloHCT.

VI. To characterize quality of life using 36-Item Short Form Health Survey (SF-36), Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT), and M. D. Anderson Symptom Inventory (MDASI) or Pediatric Quality of Life Inventory (PedsQL) at 100 days, 6 months, 1- and 2-years post alloHCT.

VII. To assess bone marrow cellularity from bone marrow samples. VIII. To assess the clonogenic potential of cells from bone marrow samples. IX. To assess stromal damage from bone marrow samples. X. To evaluate cytokines and oxidative stress markers.

OUTLINE: This is a dose-escalation study of TMLI.

Patients undergo TMLI twice daily (BID) on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide intravenously (IV) over 2 hours on days 3 and 4, tacrolimus given by continuous intravenous infusion (CIV) on days 5-90, and filgrastim beginning on day 5 until absolute neutrophil count (ANC) is at least 1,500/mm^3 for 3 consecutive days.

After completion of study treatment, patients are followed for up to 24 months.

연구 유형

중재적

등록 (실제)

56

단계

  • 1단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

    • California
      • Duarte, California, 미국, 91010
        • City of Hope Medical Center

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

16년 (어린이, 성인)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • This study is open to patients with acute myeloid leukemia (AML) evaluated within 30 days of the start of conditioning regimen and in first or second complete remission (CR)
  • Karnofsky performance status (KPS) >= 70%
  • The effects of radiation on the developing fetus are known to be teratogenic; for this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for six months following duration of study participation; should a woman become pregnant or suspect that she is pregnant while participating on the trial, she should inform her treating physician immediately
  • Patients with acute myelogenous leukemia (AML) who are in first or second complete remission
  • All candidates for this study must have a human leukocyte antigen (HLA) (A, B, C, DR) identical sibling who is willing to donate primed blood stem cells (preferred) or bone marrow, or have a 10/10 allele matched unrelated donor; all ABO blood group combinations of the donor/recipient are acceptable since even major ABO compatibilities can be dealt with by various techniques; (red cell exchange or plasma exchange)
  • A cardiac evaluation with an electrocardiogram showing no ischemic changes or abnormal rhythm and an ejection fraction of >= 50% established by multi-gated acquisition scan (MUGA) or echocardiogram
  • Patients must have a serum creatinine of less than or equal to 1.3 mg/dL or creatinine clearance > 70 ml/min as calculated by the Cockcroft-Gault formula
  • A bilirubin of less than or equal to 1.5 mg/dL, excluding patients with Gilbert's disease
  • Patients should also have a serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) less than 5 times the upper limit of normal
  • Pulmonary function tests including diffusing capacity of the lung for carbon monoxide (DLCO) will be performed; forced expiratory volume in 1 second (FEV 1) and DLCO should be greater than 50% of predicted normal value
  • All subjects must have the ability to understand and the willingness to sign a written informed consent; signed informed consent form approved by the Institutional Review Board (IRB) is required; the patient, family member, and transplant staff physician (physician, nurse, and social worker) meet at least once prior to starting the transplant procedure; during this meeting, all pertinent information with respect to risks and benefits to the donor and recipient will be presented; alternative treatment modalities will be discussed
  • The time from the end of last induction, re-induction, or consolidation regimen should be greater than or equal to 14 days
  • Prior therapy with etoposide and cyclophosphamide is allowed
  • DONOR: donor evaluation and eligibility will be assessed as per current City of Hope standard operating procedure (SOP)

Exclusion Criteria:

  • Patients should not have any uncontrolled illness including ongoing or active or poorly controlled infection
  • Patients may not be receiving any other investigational agents, or concurrent biological, chemotherapy, or radiation therapy; maintenance therapy with Food and Drug Administration (FDA)-approved targeted therapies (e.g. tyrosine kinase inhibitors for Philadelphia chromosome [Ph] positive [+] acute lymphoblastic leukemia [ALL], and FLT inhibitors for FLT3+ patients) will be allowed after day 60 disease assessment
  • Prior radiation therapy that would exclude the use of TMLI
  • Relapsed patients who have undergone autologous or allogeneic hematopoietic stem cell transplantation previously
  • Patients with psychological or medical condition that patient's physician deems unacceptable to proceed to allogeneic hematopoietic stem cell transplantation
  • Electrocardiogram (EKG) showing ischemic changes or abnormal rhythm and/or an echocardiogram or MUGA scan showing abnormal wall motion or ejection fraction < 50%
  • Patients who have been treated with chemotherapy or radiation for the purpose of induction, re-induction or consolidation, within two weeks of planned study enrollment
  • Patients with other active malignancies are ineligible for this study, other than localized malignancies
  • Patients that are pregnant or breastfeeding
  • Any other condition that would, in the investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, including but not limited to, infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.
  • Subjects, who in the opinion of the investigator, may not be able to comply with the safety monitoring requirements of the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Treatment (TMLI, cyclophosphamide)

Patients undergo TMLI BID on days -4 to 0, then undergo bone marrow or peripheral blood stem cell transplant on day 0. Patients receive cyclophosphamide IV over 2 hours on days 3 and 4, tacrolimus given by CIV on days 5-90, and filgrastim beginning on day 5 until ANC is at least 1,500/mm^3 for 3 consecutive days.

Correlative studies

Ancillary studies

다른 이름들:
  • 삶의 질 평가

Given IV

다른 이름들:
  • 사이톡산
  • CTX
  • (-)-시클로포스파미드
  • 2H-1,3,2-옥사자포스포린, 2-[비스(2-클로로에틸)아미노]테트라하이드로-, 2-옥사이드, 일수화물
  • 칼록산
  • 시클로포스파미다
  • 시클로포스파마이드
  • 시클록살
  • 클라펜
  • CP 일수화물
  • CYCLO 셀
  • 사이클로블라스틴
  • 사이클로포스팜
  • 사이클로포스파미드 일수화물
  • 사이클로포스파미둠
  • 시클로포스판
  • 사이클로포스판
  • 시클로포스파늄
  • 사이클로스틴
  • 사이토포스판
  • 포스파세론
  • 제녹살
  • 제눅살
  • 레독시나
  • 미톡산
  • 네오사르
  • 리바이뮨
  • 실클로포스파미드
  • WR-138719

Ancillary studies

Undergo alloHCT

다른 이름들:
  • 동종 조혈 세포 이식
  • 동종 줄기 세포 이식
  • HSC
  • 조혈모세포이식
  • 줄기 세포 이식, 동종

Administer according to City of Hope standard operating procedures

다른 이름들:
  • G-CSF
  • r-metHuG-CSF
  • 뉴포겐
  • 재조합 메티오닐 인간 과립구 콜로니 자극 인자
  • rG-CSF
  • 테바그라스팀

Given CIV

다른 이름들:
  • 프로그라프
  • 헤코리아
  • FK 506
  • 후지마이신
  • 프로토픽

Undergo TMLI

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
1a. Incidence of adverse events
기간: Up to 24 months

Assessed using Bearman Scale Regimen-Related Toxicity scale. Scale range: Grade 0-4 (increasing grade reflects increasing severity), where Grade 0-none/did not experience and Grade 4=death.

Up to 24 months
1b. Incidence of adverse events
기간: Up to 24 months

Assessed using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 scale. Scale range: Grade 1-5 (increasing grade reflects increasing severity), where Grade 1 reflects a more milder form of the adverse event and Grade 5=death.

Up to 24 months

2차 결과 측정

결과 측정
측정값 설명
기간
호중구 및 혈소판 회복/생착까지의 시간
기간: 0일부터 회복 또는 생착 실패 선언까지, 최대 24개월까지 평가
0일부터 회복 또는 생착 실패 선언까지, 최대 24개월까지 평가
골수 잔류 손상 평가
기간: 최대 24개월
최대 24개월
사이토카인
기간: 최대 24개월
최대 24개월
산화 스트레스 마커
기간: 최대 24개월
최대 24개월
Acute graft versus host disease (GvHD)
기간: Day 0 to 100 (120) days post-transplant

Graded according to the Consensus Grading. The first day of acute GvHD onset at a certain grade will be used to calculate cumulative incidence curves for that GvHD grade; relapse/death prior to onset will be considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999).

Day 0 to 100 (120) days post-transplant
Chronic GVHD
기간: From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months

The first day of chronic GvHD onset will be used to calculate cumulative incidence curves, with relapse/death prior to onset considered competing events. Will be calculated using the competing risk method as described by Gooley et al. (1999).

From day (80) 100 to the onset of chronic GvHD, death or last contact, whichever comes first, assessed up to 24 months
GvHD-free/relapse-free survival (GRFS)
기간: From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months

Will be calculated using the Kaplan-Meier method.

From start of treatment (hematopoietic stem cell transplant [HCT]) to grade 3-4 acute GvHD, chronic GvHD requiring systemic treatment, relapse, or death (from any cause), whichever occurs first, assessed p to 24 months
Levels of immune cells
기간: Up to 24 months

Will be measured by flow cytometry for cell subsets: a. T-cells.

Up to 24 months
Levels of immune cells
기간: Up to 24 months

Will be measured by flow cytometry for cell subsets: b. B-cells.

Up to 24 months
Levels of immune cells
기간: Up to 24 months

Will be measured by flow cytometry for cell subsets: c. natural killer (NK) cells.

Up to 24 months
Levels of immune cells
기간: Up to 24 months

Will be measured by flow cytometry for cell subsets: d. regulatory T cells (T-regs).

Up to 24 months
Overall survival
기간: From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months

Will be calculated using the Kaplan-Meier method.

From start of treatment until death, or last follow-up, whichever comes first, assessed up to 24 months
Relapse-free survival
기간: From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months

Will be calculated using the Kaplan-Meier method.

From the start of treatment to the date of death, disease relapse, or last follow-up whichever occurs first, assessed up to 24 months
Relapse
기간: From start of therapy, assessed up to 24 months

Will be calculated using the competing risk method as described by Gooley et al. (1999).

From start of therapy, assessed up to 24 months
Non-relapse mortality (NRM)
기간: From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months

The cumulative incidence of NRM will be calculated reflecting relapse as a competing risk. Will be calculated using the Kaplan-Meier method and the competing risk method as described by Gooley et al. (1999).

From start of treatment until non-disease related death, or last follow-up, whichever comes first, assessed up to 24 months
Quality of life -Questionnaire
기간: Up to 24 months

Assessed using a. 36-Item Short Form Health Survey (SF-36). The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.

The eight sections are:

  • a1. vitality
  • a2. physical functioning
  • a3. bodily pain
  • a4. general health perceptions
  • a5. physical role functioning
  • a6. emotional role functioning
  • a7. social role functioning
  • a8. mental health
Up to 24 months
Quality of life-Function Assessment
기간: Up to 24 months

Assessed using b. Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT). (FACT-BMT) is a 47-item, valid and reliable measure of five dimensions of quality of life in bone marrow transplant patients. The dimensions collected and assessed are:

  • b1.physical well being
  • b2. Social and family well being
  • b3. Emotional well being
  • b4. Functional well being
  • b5. Additional concerns.
Up to 24 months
Quality of life -Symptom Inventory
기간: Up to 24 months

Assessed using c. M. D. Anderson Symptom Inventory (MDASI). MDASI is a multi-symptom patient-reported outcome (PRO) measure for clinical and research use. Use the MDASI to assess the severity of symptoms experienced by patients with cancer and the interference with daily living caused by these symptoms. The following parameters will be reported:

  • c1a. Pain
  • c1b. Fatigue
  • c1c. Nausea
  • c1d. Disturbed sleep
  • c1e. Distress/feeling upset
  • c1f. Shortness of breath
  • c1g. Difficulty remembering
  • c1h. Lack of appetite
  • c1i. Drowsiness
  • c1j. Dry mouth
  • c1k. Sadness
  • c1l. Vomiting
  • c1m. Numbness/tingling
  • c1n. Walking
  • c1o. Activity
  • c1p. Working (including housework)
  • c1q. Relations with other people
  • c1r. Enjoyment of life
  • c1s. Mood A total of eight quality of life parameters will be reported on each pediatric transplant patient.
  • c2a.Pain and Hurt
  • c2b. Fatigue and Sleep
  • c2c. Nausea
  • c2d. Worry
  • c2e. Nutrition
  • c2f. Thinking
  • c2g. Communication
Up to 24 months

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Anthony S Stein, City of Hope Medical Center

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 3월 19일

기본 완료 (추정된)

2027년 4월 12일

연구 완료 (추정된)

2027년 4월 12일

연구 등록 날짜

최초 제출

2018년 2월 22일

QC 기준을 충족하는 최초 제출

2018년 3월 9일

처음 게시됨 (실제)

2018년 3월 16일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 30일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다